Clinical Trial

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).
Protocol Amendment History 1 change
notable Trial sites expanded: 40 -> 49 locations 2026-07-25
Trial Details
NCT Number NCT06568367
Lead Sponsor Axsome Therapeutics, Inc.
Conditions Excessive Sleepiness, Shift-work Disorder
Enrollment 520 participants
Start Date 2024-08-01
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-24